[Edaily Reporter Kim Seung-kwon ] On the 13th, the domestic pharmaceutical, biotech, and healthcare sectors saw strong buying momentum driven by a combination of expectations for explosive growth from newly listed medical device companies, key themes in the global pharmaceutical market, and positive developments originating in the U.S.

While the KOSDAQ index rose only slightly, in the 1% range, the companies that drew the most attention were #SkyLabs, #SAMIK PHARM. Co., LTD., and #L&K BIOMED CO., LTD. In particular, SkyLabs—which overcame a sluggish public offering to surge for two consecutive days after its listing, reaching a share price more than three times its offering price—has been reevaluated as a “game-changer” set to transform the paradigm of chronic disease management and has emerged as a market leader.

SkyLabs Soars for Two Consecutive Days After Reversing Initial Public Offering Slump… “Ring-Type Blood Pressure Monitor” Technology Re-evaluated

According to KG Zeroin MP Doctor on that day, SkyLabs closed at the daily price limit of 30,550 won, up 30.00% (7,050 won) from the previous trading day. Buying pressure was so intense that the Volatility Interruption (VI) mechanism was triggered twice during the session, and trading volume exceeded 660 billion won in the morning alone. Compared to the initial public offering (IPO) price of 10,000 won, this represents a staggering 205.5% surge, marking the second consecutive day of gains following a 135.0% rise from the IPO price on its first day of listing on the 4th.

SkyLabs’ performance has completely overturned the slump seen during the initial public offering (IPO) process. Previously, the institutional book-building competition ratio stood at 63.41 to 1, and the mandatory lock-up commitment rate was a mere 0.17%, raising concerns about an overhang (potential selling pressure) immediately after the listing. However, the actual market saw a surge of strong buying momentum that far outweighed these concerns. The direct cause of the stock price rise was the spotlight on the unparalleled clinical data for the “CART BP pro,” the world’s first cuffless blood pressure monitor to simultaneously receive medical device certification and health insurance coverage.

On that day, SkyLabs announced that it had presented the results of five CART-related studies involving patients with atrial fibrillation, heart failure, and sleep apnea at the European Society of Cardiology (ESC) Congress 2026, recently held in Munich, Germany. Notably, a study by Professor Kim In-cheol of Keimyung University Dongsan Hospital on patients with severe heart failure met the accuracy standards set by the European Society of Hypertension (ESH), while Professor Yoon Jong-chan of Seoul St. Mary’s Hospital captured the pattern of blood pressure rise immediately following the restoration of breathing in patients with sleep apnea. The market interpreted this as a strong medium- to long-term growth driver that could expand the device’s scope of application—previously limited to hypertension management—to cardiovascular diseases in general.

Lee Byung-hwan, CEO of SkyLabs, explained, “It wasn’t that the company or the technology was undervalued; rather, it seems we started out undervalued because the initial public offering wasn’t well-received at the time.”

SAMIK PHARM. Co., LTD. Rides Wall Street’s ‘Hair Loss Rally’ for a 30% Surge… Next-Generation Long-Acting Platform Takes Center Stage

SAMIK PHARM. Co., LTD. also soared 30.03% (2,020 won) from the previous trading day, hitting the daily price limit at 8,780 won. Trading volume exceeded 4.19 million shares during the morning session alone, reflecting explosive market demand. The direct catalyst driving up SAMIK PHARM. Co., LTD.’s stock price was the emergence of a new investment theme centered on “hair loss treatments,” originating from Wall Street in the U.S. Recently, Bloomberg identified companies developing new hair loss treatments as the “next Wegovy,” drawing global investment interest. Meanwhile, in the domestic market, this coincided with momentum from the review of expanded National Health Insurance coverage, causing related stocks to surge across the board.

SAMIK PHARM. Co., LTD.’s core technological strength lies in its drug delivery platform (Patent No. 2905826), which converts “baricitinib”—a JAK inhibitor used to treat alopecia areata and rheumatoid arthritis—from a daily oral medication into a long-acting injectable administered once a month. This is a highly sophisticated formulation technology that loads more than 95% of a poorly water-soluble drug into polymer microparticles and controls its release to maintain a consistent concentration for at least one month.

However, in contrast to the rising stock price, the company is maintaining a somewhat cautious stance. SAMIK PHARM. Co., LTD. official drew a line regarding the long-acting technology, stating, “It will take a considerable amount of time before commercialization,” and explained that the recent sharp rise in the stock price is attributed to “fluctuations in supply and demand” rather than any specific positive news.

In fact, SAMIK PHARM. Co., LTD. has a large proportion of shares held by its largest shareholder and related parties—approximately 63%—making it a “scarce stock” with limited trading volume; as a result, even small capital inflows can cause extreme volatility in its stock price. A securities industry official pointed out, “Most of the new hair loss drugs generating anticipation in the U.S. are still in the clinical trial or approval stages,” adding, “Along with verifying the stability of formulation technology, we need to calmly assess whether theme-driven supply and demand will actually translate into increased earnings.”

L&K BIOMED CO., LTD. Secures Additional FDA Approval Targeting Market Needs… Accelerates Penetration of U.S. Spine Market

L&K BIOMED CO., LTD.(156100)The stock staged a strong rally, trading around 5,100 won—up in the 20% range compared to the previous trading day. It surged as high as 5,400 won during the session, showing a clear upward trend. Regarding the sharp rise in the stock price despite the absence of any new announcements that day, industry analysts unanimously stated, “This is believed to reflect strong market expectations regarding earnings growth in the U.S. market and progress on large-scale supply contracts with major global companies.”

L&K BIOMED CO., LTD.’s short-term upward momentum and medium- to long-term growth drivers lie in its “products localized for the U.S. market.” Last month, the company expanded the footprint (the base area in contact with the bone) of its cervical height-expandable cage, “BluEX-C,” and swiftly secured additional approval from the U.S. FDA. By adding the ability to select the base area according to the patient’s anatomical characteristics—in addition to the existing functionality of increasing height from 4 mm to a maximum of 15 mm during surgery—the company has met the strong demand from U.S. surgeons to reduce the side effect of postoperative bone subsidence.

Additionally, the fact that “Factus,” an implant for correcting chest wall deformities, surpassed monthly sales of 1 billion won and secured references from institutions such as the Mayo Clinic also had a positive impact. Analysts note that the company’s solid core business competitiveness—which has maintained a profitable trend for two consecutive quarters—is firmly supporting the stock price against downside risks.

However, the variable the market is watching most closely is the timing of the signing of a supply contract with a major global medical device company, with which due diligence has been completed and negotiations for the main contract are currently underway. Some analysts in the securities industry noted, “If the global contract is finalized, sales channels will expand explosively into Southeast Asia and Europe; however, the possibility of protracted negotiations and the overhang issue related to the potential supply of 32 billion won worth of convertible bonds (CBs) are risks that must be continuously monitored.”